Compare FIEE & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FIEE | GRML |
|---|---|---|
| Founded | 1977 | N/A |
| Country | Hong Kong | United States |
| Employees | 3 | 5 |
| Industry | Telecommunications Equipment | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.7M | 34.9M |
| IPO Year | N/A | 2022 |
| Metric | FIEE | GRML |
|---|---|---|
| Price | $3.65 | $0.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.2K | ★ 3.7M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $0.16 |
| 52 Week High | $7.95 | $0.55 |
| Indicator | FIEE | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 41.78 | N/A |
| Support Level | $2.43 | N/A |
| Resistance Level | $4.14 | N/A |
| Average True Range (ATR) | 0.25 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 38.10 | 0.00 |
FiEE Inc is a digital service provider focused on integrating artificial intelligence (AI) and data analytics into content creation, digital authentication, and brand management. Its business model leverages a cloud-based SaaS platform designed to support clients in developing, managing, and optimizing their digital presence across platforms, including customized graphics and posts, short videos, and editorial calendars aligned with brand goals. Additionally, it offers comprehensive software development and maintenance services, delivering custom software solutions from system design and development to deployment and post-launch maintenance. It services consist of three core areas: digital content and MCN services, software development services, and digital authentication services.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.